Researchers wrote that they observed "substantial and increasing disparities in CVD between people with the most resources and the remainder of the U.S. population."
The study tracked nearly 500 patients for more than two decades.
Recurrent coronary heart disease is also on the decline, according to a new analysis published in Circulation.
The designation covers patients with and without diabetes.
The analysis was presented at ESC Congress 2020 and published in JACC: CardioOncology.
The AI algorithm was trained using photographs of more than 5,000 patients.
The authors tracked more than 108,000 patients who suffered their first heart attack between 2009 and 2013.
The wearable devices were designed to detect such conditions as cardiovascular disease, coronary artery disease and ischemic heart disease.
This new analysis of the ODYSSEY OUTCOMES trial includes data from more than 18,000 patients.
The ThyrAMI-2 trial tracked 95 patients for 52 weeks of treatment.
The peptide-derived drug, M3mP6 HLPN, prevents blood clots without increasing the risk of bleeding.
The risk score was found to be considerably accurate, providing results that matched the work of prior researchers.